Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
756 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Nowak RJ, Benatar M, Ciafaloni E, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF, Bril V, Vu T, et al. · Lancet Neurol · 2021Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Antozzi C, Vu T, Ramchandren S, et al. · Lancet Neurol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, et al. · Lancet Neurol · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Randomized Trial of Thymectomy in Myasthenia Gravis.
Wolfe GI, Kaminski HJ, Aban IB, et al. · N Engl J Med · 2016Comparative Study, Multicenter Study
- Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF, Bresch S, Genge A, et al. · Lancet Neurol · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.
Salari N, Fatahi B, Bartina Y, et al. · J Transl Med · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Vu T, Meisel A, Mantegazza R, et al. · NEJM Evid · 2022Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.
Gwathmey KG, Saccà F, Howard JF, et al. · JAMA Neurol · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review.
Sciancalepore F, Sciancalepore F, Lombardi N, et al. · Neuroepidemiology · 2025Systematic Review
- Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V, Benatar M, Kurtoglu M, et al. · Lancet Neurol · 2023Clinical Trial, Phase I, Clinical Trial, Phase II
- Immunoglobulin for myasthenia gravis.
Manolopoulos A, Alzuabi M, Elmashala A, et al. · Cochrane Database Syst Rev · 2025Systematic Review, Meta-Analysis
- Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Howard JF, Vu T, Li G, et al. · Neurotherapeutics · 2024Clinical Trial, Phase III, Equivalence Trial
- Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and metaߛanalysis.
Akhtar M, Akhtar M, Farooqi HA, et al. · Clin Neurol Neurosurg · 2025Systematic Review, Meta-Analysis
- Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Saccà F, Pane C, Espinosa PE, et al. · Eur J Neurol · 2023Systematic Review, Network Meta-Analysis
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H, Johnson DH, Trinh VA, et al. · J Immunother Cancer · 2019Research Support, N.I.H., Extramural, Systematic Review
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF, Bril V, Burns TM, et al. · Neurology · 2019Clinical Trial, Phase II, Randomized Controlled Trial
- Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R, Katel A, Massarelli E, et al. · Oncologist · 2021Systematic Review
- Nipocalimab Dose Selection in Generalized Myasthenia Gravis.
Valenzuela B, Neyens M, Zhu Y, et al. · CPT Pharmacometrics Syst Pharmacol · 2025Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A, Annane D, Vu T, et al. · J Neurol · 2023Clinical Trial, Phase III
- A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.
Yin J, Zhao M, Xu X, et al. · Eur J Neurol · 2024Randomized Controlled Trial, Multicenter Study
- Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.
Vu TH, Mantegazza R, Annane D, et al. · Eur J Neurol · 2025Multicenter Study, Randomized Controlled Trial
- Inspiratory muscle training and aerobic exercise for respiratory muscle strength in myasthenia gravis post-hospitalization- a randomized controlled trial.
Chang CL, Fang TP, Tsai HM, et al. · BMC Pulm Med · 2025Randomized Controlled Trial
- Transcervical thymectomy.
Ferguson MK · Semin Thorac Cardiovasc Surg · 1999Meta-Analysis
- Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis.
Gu J, Qiao Y, Huang R, et al. · J Transl Med · 2024Systematic Review, Network Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.